Finland drug prices: Hila decisions and the reasonable wholesale price

Finland has three medicine price sources, and the one most summaries name is the least useful of them. The monthly decision lists are good, the consumer search application is unusable for any pipeline, and the third source, an open interface published by the national health insurance institution under a free licence, is better than both. It also carries the best structured pack data of any Nordic source we examined.

The three sources, ranked

The pricing board's monthly lists. Reimbursable authorised medicines with their prices, published as a spreadsheet, one file per month. The August 2026 file carries 5,945 pack rows across 17 columns, plus a field documentation sheet and a translation sheet with 457 dosage form terms in Finnish, Swedish and English.

The medicines search of the insurance institution. Retail prices, updated on the 1st and the 15th of each month. It is a legacy form based application with no bulk export and no documented interface, and the site's own crawl rules disallow the relevant areas. It is not a pipeline source.

The medicinal products database published through the national patient data service. A REST interface, no registration, CC BY 4.0, with a version list endpoint and a full download endpoint. We retrieved the full dataset on 5 September 2026 at HTTP 200 and 1,776,089 bytes. It contains what is needed for prescribing and dispensing, covering both prescription and over the counter products, and the search application above is itself built on it.

For anyone building a Finnish pipeline, the third source is the answer and the second one is redundant.

Two wholesale columns, not one

The pricing board's file carries two separate wholesale figures: a confirmed reasonable wholesale price and the wholesale price actually charged at the pharmacy. They are different fields with different meanings, and collapsing them into a single price column throws away the distinction between what was approved and what applies.

The rule is the same one that applies in Belgium with its official and real ex-factory prices: keep the published fields apart, and derive a preferred value at query time rather than at import.

The history that no other Nordic country offers

The pricing board keeps yearly archives from 2014 through 2026, each as its own page with monthly files. That makes a month by month Finnish price history of more than ten years reloadable at any time.

This is unique in the Nordic group. Denmark's history exists only from the start of your own subscription, Sweden's bulk download is always the current state, and Norway publishes a periodic history overview rather than a full monthly series. If a project needs a European price time series, Finland is where it can actually be built rather than accumulated.

The back calculation, step by step

From the consumer price including tax, three operations lead to the manufacturer level.

Remove the dispensing fee first. A fee of 2.46 euro is added to each prescribed product bought at a pharmacy. It is not part of the price scale, so it has to come off before anything else. Gross 2.46 euro corresponds to 2.17 euro net at the current tax rate.

Remove VAT at 13.5 percent. In force since 1 January 2026. The authority file names the rate itself, and we recalculated it across 5,945 rows.

Remove the pharmacy scale, then the distribution margin of 3 percent. The scale has six bands with fixed components, anchored in the government decree on the medicine tariff.

The band is selected by the selling price, not by the purchase price. That is not an assumption: under the selling price reading the scale is continuous at every band edge, with a largest jump of 0.0032 euro, which is rounding. Under the other reading the same scale jumps by up to 12.73 euro. The continuity test settles it.

The final 3 percent step rests on an Austrian administrative regulation used as a substitute assumption rather than on Finnish law, so the manufacturer level figure is an estimate and should be labelled as one.

A worked example of the full chain

Take a Finnish consumer price of 60.00 euro for a prescribed pack.

1. Remove the dispensing fee. 60.00 minus 2.46 leaves 57.54 euro.
2. Remove VAT at 13.5 percent. 57.54 divided by 1.135 gives 50.70 euro.
3. Apply the scale. 50.70 euro falls in the second band, so subtract the fixed component of 0.52 euro and divide by 1.33, giving 37.73 euro.
4. Remove 3 percent distribution margin. The result is roughly 36.60 euro at manufacturer level.

Four operations, three legal bases and one foreign substitute assumption. The first three steps are defensible in Finnish law. The fourth is not, which is precisely why the result has to be labelled as an estimate and the first three levels kept in the data model as well.

The example also shows why the order matters. Removing VAT before the dispensing fee would apply the tax rate to a fee that is not part of the price scale, and the error would be small, constant and undetectable in aggregate.

Two traps in the Finnish data

Leading zeros in the article number. The pricing board's file drops leading zeros from the Nordic article number, leaving 28 percent of rows too short. A join that compares the raw strings will fail on more than a quarter of the file for a reason that has nothing to do with the products. Normalise the length before matching.

The monthly file is not there on the first of the month. On 3 September 2026 the September file had not yet appeared. A fetch scheduled for the first of the month will retrieve nothing, and a pipeline that treats an empty result as an empty market will publish a gap.

There is also a positive detail worth noting: the Finnish pack data model is the best in the Nordic group, and the open interface publishes checksums, which lets a pipeline verify an extract rather than trust it.

Why the translation sheet matters

One column of the pricing board's file is easy to overlook and unusually valuable for a multilingual product: a sheet with 457 dosage form terms in Finnish, Swedish and English.

Dosage form vocabulary is one of the recurring cost centres in cross-country pharmaceutical data, because every national source uses its own wording and a mapping has to be built by hand. Finland ships part of that mapping in the same file as the prices, maintained by the body that publishes them.

For a European dataset that is worth more than it looks. It gives an authoritative anchor for three languages at once, and it can be reused as a reference when normalising terms from sources that publish in one language only.

What Finland does not give you

No GTIN, and none that can be derived. The Nordic article number carries the join.

No manufacturer price, as everywhere in the region. What can be published without a caveat is the wholesale level, which is stated directly.

No coverage of the non-reimbursed segment in the pricing board's lists, although the open database from the insurance institution does include over the counter products, which narrows that gap considerably.

A checklist for Finnish prices

1. Build on the open interface from the national patient data service, not on the consumer search application.
2. Keep the two wholesale columns of the pricing board file as separate fields.
3. Remove the dispensing fee before tax and margins.
4. Use 13.5 percent VAT with its effective date of 1 January 2026.
5. Select the pharmacy scale band by the selling price, and verify continuity at every edge yourself.
6. Normalise the article number length before joining, because leading zeros are dropped in one source.
7. Do not fetch the monthly file on the first of the month.
8. Label the manufacturer level as an estimate based on a 3 percent assumption, with the rule version.

Conclusion

Finland rewards anyone who looks past the obvious source. An open, freely licensed interface delivers structured pack data with checksums, a ten year monthly archive makes a real price history possible, and the conversion rules are documented well enough to be tested rather than believed. What remains are two mechanical traps, a missing GTIN and the same regional limitation as everywhere else: the manufacturer price is an estimate, not a publication.

Related reading: European Drug Pricing Database: how cross-border prices work and Pharma pricing Germany: how the system works, plus VAT on medicines in Europe and wholesale and pharmacy margins.

pharmazie.com is the consolidated pharmaceutical data platform by DACON Datenbank Consulting GmbH that bundles 25+ specialist databases into a single search, exclusively for healthcare professionals. Price coverage focuses on the DACH region and a number of further EU countries, with more countries following in the coming months.